Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
Rhea-AI Summary
Ovid Therapeutics (Nasdaq: OVID) will host a KCC2 Deep Dive R&D event on Tuesday, April 14, 2026 at 9:30 am ET in New York, with a simultaneous webcast. The session will review Ovid's first-in-class KCC2 portfolio, pharmacodynamic data, translational and clinical strategy, and market potential.
Speakers include CEO Meg Alexander, independent clinicians, translational experts, and leading neuroscientists; a webcast replay will be archived for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – OVID
In the Apr 8 session, OVID gained 1.56%, reflecting a mild positive market reaction. Argus tracked a peak move of +13.6% during that session. Our momentum scanner triggered 61 alerts that day, indicating high trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Data & earnings | Positive | +14.4% | OV329 data, OV4071 Phase 1 clearance, and 2025 financial results. |
| Mar 18 | Private placement | Neutral | +14.4% | Announcement of $60.0M PIPE financing and related share, warrant terms. |
| Feb 25 | Investor conferences | Positive | +7.3% | Participation in three investor conferences with webcast access. |
| Dec 18 | Phase 1 results | Neutral | -9.5% | OV350 Phase 1 safety/PK success but IV program not advanced further. |
| Dec 02 | Leadership change | Positive | -13.3% | Appointment of Dr. Petra Kaufmann as Chief Medical Officer. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent OVID news often drew sizable moves, with generally positive reactions to data/financing updates but occasional selloffs on leadership or pipeline restructuring headlines.
Over the past six months, OVID has highlighted key CNS pipeline advances and financing. On Mar 18, 2026, OV329 data, OV4071 Phase 1 clearance, and 2025 results coincided with a 14.43% gain, alongside a $60.0M private placement the same day that saw a similar move. Earlier, conference participation on Feb 25, 2026 led to a 7.28% rise. In late 2025, OV350 Phase 1 results and the decision not to advance the IV program, plus a CMO appointment, saw declines. Today’s KCC2 R&D event builds directly on this KCC2-focused narrative.
Key Terms
potassium-chloride co-transporter 2 (KCC2) medical
KCC2 medical
pharmacodynamic medical
translational medical
neuropsychiatric medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the Company will host a KCC2 Deep Dive R&D event highlighting its first-in-class KCC2 portfolio on Tuesday, April 14, 2026, at 9:30 am ET in New York, NY, which will also be webcast simultaneously.
During the event independent expert clinicians and translational experts as well as Ovid’s President and Chief Executive Officer Meg Alexander, will discuss the Company’s proprietary portfolio of potential first-in-class direct activators of KCC2, including pharmacodynamic data, translational and clinical development strategy, and the potential market opportunity. Ovid is developing a portfolio of unique molecules, which include OV350 (an intravenous tool program and KCC2 direct activator), OV4071 (an oral KCC2 direct activator) and next-generation development candidates that have differentiated potential therapeutic profiles and formulations. These direct activators have the potential to become broad franchises of medicines for neurological and neuropsychiatric conditions including various psychoses, epilepsies, and neurodevelopmental and neurodegenerative disorders.
The event will also feature remarks from multiple leading neuroscientists, including:
- Michael Halassa, M.D., Ph.D., Professor, Patient Research Center, Fralin Biomedical Research Institute at VTC, Department of Psychiatry and Behavioral Medicine, Virginia Tech Carilion School of Medicine, Department of Biomedical Engineering, College of Engineering, Virginia Tech
- Oliver Howes, M.B.B.S., Ph.D., Head of Department, Psychosis Studies, Professor of Molecular Psychiatry at the Institute of Psychiatry, Psychology & Neuroscience, King's College London
- Eliseo Oeste Salinas, M.D., M.s.C., Senior R&D Advisor to Ovid and veteran drug developer
Webcast Information
Ovid will host a live webcast of the event at 9:30 am ET on Tuesday, April 14, 2026.
The live webcast of the event can be accessed through the Events & Presentations section of Ovid’s website. Participants may register for the webcast here and are advised to do so at least 10 minutes prior to joining the event. A replay of the webcast will be archived on Ovid’s website for 90 days following the event.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain disorders with significant unmet need. Ovid is advancing a pipeline of novel targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant focal onset seizures (FOS) and developmental and epileptic encephalopathies (DEEs), including tuberous sclerosis complex (TSC) and infantile spasms (IS); and OV4071 and others within a library of compounds that directly activate the KCC2 transporter for multiple CNS disorders. For more information about these and other Ovid research programs, please visit www.ovidrx.com.
Contact
Investor Relations & Media
Victoria Fort
VFort@ovidrx.com
202.361.0445
